Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 1,200
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Allon Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing and marketing central nervous system therapies. Its preclinical drug candidate comprises AL-309 for the treatment of peripheral neuropathy. The company was formerly known as Neuro Discovery Inc. and changed its name to Allon Therapeutics Inc. in September 2004. Allon Therapeutics Inc. was incorporated in 1994 and is headquartered i...
Show more
Allon Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing and marketing central nervous system therapies. Its preclinical drug candidate comprises AL-309 for the treatment of peripheral neuropathy. The company was formerly known as Neuro Discovery Inc. and changed its name to Allon Therapeutics Inc. in September 2004. Allon Therapeutics Inc. was incorporated in 1994 and is headquartered in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 604-736-0634
- Website
- https://www.allontherapeutics.com
- Address
- 1168 Hamilton Street, Suite 506, Vancouver, Canada
Latest news
No headlines yet.
